ClinicalTrials.gg
CompletedNCT06602219Updated Aug 18, 2026Results posted

A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 2 interventional study of LY4100511 and Placebo in Plaque Psoriasis, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 58 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Enrollment
13th of 36
222 · median 181
Started
2024
with 1 other
Phase 2
9 of 36
none open now
Registered
34th of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 13th largest by enrollment, is one of 2 that started in 2024, is one of 9 in phase 2, and was the 34th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization
  • Must have a (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).
  • Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.
  • Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study

Exclusion criteria

Exclusion Criteria:

  • Have had a flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator.
  • Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.
  • Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.
  • Have a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic medical treatment (including , immunosuppressants, and biologics).
  • Have a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    LY4100511 200 mg BID

    Participants received LY4100511 200 milligrams (mg) administered orally twice daily (BID) for 12 weeks.

    Drug: LY4100511

  • Experimental
    LY4100511 400 mg BID

    Participants received LY4100511 400 mg administered orally BID for 12 weeks.

    Drug: LY4100511

  • Experimental
    LY4100511 800 mg QD

    Participants received LY4100511 800 mg administered orally once daily (QD) for 12 weeks, with matching placebo administered in the evening.

    Drug: LY4100511

  • Placebo comparator
    Placebo BID

    Participants received placebo administered orally BID for 12 weeks.

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo)

    Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 200mg vs 400mg vs 800mg)

    Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Week 12

  2. Percentage of Participants Achieving an sPGA Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 12

    Percentage of participants achieving a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 12. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): * 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur * 1 = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling * 2 = Mild: Pink to light red color; slight thickening; mainly fine scaling * 3 = Moderate: Dull bright red erythema; moderate thickening; moderate scaling * 4 = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions

    Time frame: Week 12

  3. Percentage of Participants Achieving ≥50% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-50) at Week 12

    Percentage of participants achieving ≥50% reduction from baseline in PASI-50 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Week 12

  4. Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12

    Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Week 12

  5. Percentage of Participants Achieving ≥90% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12

    Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Week 12

  6. Percentage of Participants Achieving ≥100% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 12

    Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Week 12

  7. Change From Baseline in PASI Score at Week 12

    Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Baseline, Week 12

  8. Percent Change From Baseline in PASI Score at Week 12

    Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Baseline, Week 12

  9. Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 12

    Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline BSA, prior biologic therapy (Yes/No), geographic region, and baseline BMI, baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

  10. Percent Change From Baseline in the Percentage of BSA Affected at Week 12

    Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline BSA, prior biologic therapy (Yes/No), geographic region, and baseline BMI, baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

  11. Pharmacokinetics (PK): Steady State Maximum Concentration of LY4100511 (Cmax,ss)

    Steady State Maximum Concentration of LY4100511 (Cmax,ss) is reported.

    Time frame: Day 1: Predose, 0.5, 1 hours postdose; Day 15: Predose, 0.5, 1, 4 hours postdose; Day 57: Predose, 0.5, 1, 4 hours postdose

  12. Pharmacokinetics (PK): Steady State Trough Concentration (Ctrough,ss) of LY4100511

    Ctrough,ss of LY4100511

    Time frame: Predose at Day 8, 15, 29, 57 and 85

  13. Number of Participants With TEAEs and SAEs Observed During the Study of LY4100511

    The number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) observed during the study of LY4100511. A TEAE is defined as an AE that occurs during or after the first study drug administration and up to and including the follow-up visit. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: * Results in death * Is life-threatening (risk of death at the time of the event) * Requires inpatient hospitalization or prolongation of existing hospitalization (excluding elective admission for a stable pre-existing condition) * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Other medically important event that may jeopardize the participant or require intervention to prevent the above outcomes

    Time frame: Baseline up to Week 12

07

Results

Posted Aug 18, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Started55555656
Safety analysis population (received at least 1 dose of the study intervention)55545656
Completed39484949
Not completed16777
Withdrew: Adverse event3100
Withdrew: Withdrawal by subject5344
Withdrew: Eligibility criteria not met0100
Withdrew: Pregnancy0001
Withdrew: Lost to follow-up3022
Withdrew: Lack of efficacy5110
Withdrew: Request from subject0100

Outcome measures

PrimaryPercentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo)

Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo)
percentage of participantsPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo)3.631.541.144.6
Statistical analysis
  • Placebo BID vs LY4100511 200 mg BID · Fisher Exact · p = 0.0001 · Odds ratio (or): 12.18 · 95% CI 2.59 to 112.67
  • Placebo BID vs LY4100511 400 mg BID · Fisher Exact · p = <0.0001 · Odds ratio (or): 18.47 · 95% CI 4.03 to 167.80
  • Placebo BID vs LY4100511 800 mg QD · Fisher Exact · p = <0.0001 · Odds ratio (or): 21.37 · 95% CI 4.68 to 193.44
SecondaryPercentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 200mg vs 400mg vs 800mg)

Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 200mg vs 400mg vs 800mg)
percentage of participantsLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 200mg vs 400mg vs 800mg)31.541.144.6
Statistical analysis
  • LY4100511 200 mg BID vs LY4100511 800 mg QD · Fisher Exact · p = 0.1739 · Odds ratio (or): 0.57 · 95% CI 0.24 to 1.33
  • LY4100511 400 mg BID vs LY4100511 800 mg QD · Fisher Exact · p = 0.8487 · Odds ratio (or): 0.86 · 95% CI 0.38 to 1.95
  • LY4100511 200 mg BID vs LY4100511 400 mg BID · Fisher Exact · p = 0.3267 · Odds ratio (or): 0.66 · 95% CI 0.28 to 1.55
SecondaryPercentage of Participants Achieving an sPGA Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 12

Percentage of participants achieving a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 12. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): * 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur * 1 = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling * 2 = Mild: Pink to light red color; slight thickening; mainly fine scaling * 3 = Moderate: Dull bright red erythema; moderate thickening; moderate scaling * 4 = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an sPGA Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 12
percentage of participantsPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percentage of Participants Achieving an sPGA Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 121.820.426.828.6
SecondaryPercentage of Participants Achieving ≥50% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-50) at Week 12

Percentage of participants achieving ≥50% reduction from baseline in PASI-50 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥50% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-50) at Week 12
percentage of participantsPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percentage of Participants Achieving ≥50% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-50) at Week 1220.051.969.666.1
SecondaryPercentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12

Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12
percentage of participantsPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 123.631.541.144.6
SecondaryPercentage of Participants Achieving ≥90% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12

Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥90% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12
percentage of participantsPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percentage of Participants Achieving ≥90% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 121.811.117.925.0
SecondaryPercentage of Participants Achieving ≥100% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 12

Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥100% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 12
percentage of participantsPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percentage of Participants Achieving ≥100% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 1205.67.110.7
SecondaryChange From Baseline in PASI Score at Week 12

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in PASI Score at Week 12
score on a scalePlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Change From Baseline in PASI Score at Week 12-5.24 (-7.14 to -3.35)-10.01 (-11.89 to -8.14)-12.75 (-14.58 to -10.93)-11.36 (-13.18 to -9.54)
SecondaryPercent Change From Baseline in PASI Score at Week 12

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in PASI Score at Week 12
percent changePlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percent Change From Baseline in PASI Score at Week 12-28.04 (-36.83 to -19.25)-51.29 (-59.94 to -42.64)-68.49 (-76.93 to -60.06)-64.15 (-72.56 to -55.73)
SecondaryChange From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 12

Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline BSA, prior biologic therapy (Yes/No), geographic region, and baseline BMI, baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percentage of BSA
Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 12
percentage of BSAPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 12-2.82 (-5.85 to 0.20)-10.20 (-13.19 to -7.21)-11.21 (-14.13 to -8.30)-11.71 (-14.62 to -8.81)
SecondaryPercent Change From Baseline in the Percentage of BSA Affected at Week 12

Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline BSA, prior biologic therapy (Yes/No), geographic region, and baseline BMI, baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in the Percentage of BSA Affected at Week 12
Percent changePlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Percent Change From Baseline in the Percentage of BSA Affected at Week 12-10.99 (-21.17 to -0.81)-39.49 (-49.47 to -29.51)-54.83 (-64.58 to -45.09)-54.95 (-64.68 to -45.23)
SecondaryPharmacokinetics (PK): Steady State Maximum Concentration of LY4100511 (Cmax,ss)

Steady State Maximum Concentration of LY4100511 (Cmax,ss) is reported.

Time frame:
Day 1: Predose, 0.5, 1 hours postdose; Day 15: Predose, 0.5, 1, 4 hours postdose; Day 57: Predose, 0.5, 1, 4 hours postdose
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Pharmacokinetics (PK): Steady State Maximum Concentration of LY4100511 (Cmax,ss)
nanogram per millilitre (ng/mL)LY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Day 11640 ± 1673330 ± 1366550 ± 62.6
Day 151950 ± 1165370 ± 66.48060 ± 52.9
Day 571860 ± 1514890 ± 83.08670 ± 43.4
SecondaryPharmacokinetics (PK): Steady State Trough Concentration (Ctrough,ss) of LY4100511

Ctrough,ss of LY4100511

Time frame:
Predose at Day 8, 15, 29, 57 and 85
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Pharmacokinetics (PK): Steady State Trough Concentration (Ctrough,ss) of LY4100511
nanogram per millilitre (ng/mL)LY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Day 8135 ± 95.6306 ± 15295.7 ± 111
Day 15111 ± 106275 ± 21983.0 ± 105
Day 2975.2 ± 166290 ± 23773.2 ± 128
Day 57108 ± 113338 ± 99.497.1 ± 136
Day 85109 ± 163382 ± 14693.8 ± 153
SecondaryNumber of Participants With TEAEs and SAEs Observed During the Study of LY4100511

The number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) observed during the study of LY4100511. A TEAE is defined as an AE that occurs during or after the first study drug administration and up to and including the follow-up visit. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: * Results in death * Is life-threatening (risk of death at the time of the event) * Requires inpatient hospitalization or prolongation of existing hospitalization (excluding elective admission for a stable pre-existing condition) * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Other medically important event that may jeopardize the participant or require intervention to prevent the above outcomes

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and SAEs Observed During the Study of LY4100511
ParticipantsPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
TEAE's28233029
SAE's0010

Adverse events

Collected over Baseline through End of follow-up (Up to 16 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo BID0/55 (0%)0/55 (0%)28/55 (50.9%)
LY4100511 200 mg BID0/54 (0%)0/54 (0%)23/54 (42.6%)
LY4100511 400 mg BID0/56 (0%)1/56 (1.8%)30/56 (53.6%)
LY4100511 800 mg QD0/56 (0%)0/56 (0%)29/56 (51.8%)
Most frequent serious events
Most frequent serious events
EventPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
Infective corneal ulcerInfections and infestations0/550/541/560/56
Most frequent other events
Showing 10 of 116
Most frequent other events
EventPlacebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QD
NasopharyngitisInfections and infestations3/550/543/566/56
Alanine aminotransferase increasedInvestigations2/551/545/562/56
HeadacheNervous system disorders1/551/542/565/56
VomitingGastrointestinal disorders0/553/540/561/56
Upper respiratory tract infectionInfections and infestations1/553/543/561/56
DiarrhoeaGastrointestinal disorders2/551/542/563/56
FatigueGeneral disorders1/551/541/563/56
ArthralgiaMusculoskeletal and connective tissue disorders0/550/541/563/56
NauseaGastrointestinal disorders1/552/540/562/56
DizzinessNervous system disorders0/552/540/560/56

Baseline characteristics

All participants who received at least 1 dose of the study intervention.

Age, Continuous
Age, Continuous(years)Placebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QDTotal
Mean43.8 ± 11.3946.8 ± 12.7343.4 ± 12.0543.6 ± 13.8144.3 ± 12.52
Sex: Female, Male
Sex: Female, Male(Participants)Placebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QDTotal
Female1622192380
Male39323733141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QDTotal
Hispanic or Latino656421
Not Hispanic or Latino48495052199
Unknown or Not Reported10001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo BIDLY4100511 200 mg BIDLY4100511 400 mg BIDLY4100511 800 mg QDTotal
American Indian or Alaska Native00000
Asian10881036
Native Hawaiian or Other Pacific Islander00000
Black or African American00112
White43444745179
More than one race21003
Unknown or Not Reported01001
08

Study locations

58 sites
  • Cahaba Dermatology Skin Health Center
    Birmingham, Alabama 35244, United States
  • Dermatology Trial Associates
    Bryant, Arkansas 72022, United States
  • Zenith Research, Inc.
    Beverly Hills, California 90212, United States
  • First OC Dermatology Research Inc
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research
    Fremont, California 94538-1614, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Driven Research
    Coral Gables, Florida 33134, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • GCP Global Clinical Professionals, LLC
    St. Petersburg, Florida 33713-8012, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Endeavor Clinical Trials Center - Dermatology - Skokie
    Skokie, Illinois 60077-1049, United States
  • Lawrence J Green, M.D, LLC
    Rockville, Maryland 20850, United States
  • Center for Clinical Studies, LTD.LLP
    Webster, Texas 77598, United States
  • Interior Dermatology Centre - Probity - PPDS
    Kelowna, British Columbia V1W 4V5, Canada
  • Skin Care West
    Nanaimo, British Columbia V9T1W1, Canada
  • Simcoderm Medical & Surgical Dermatology Centre
    Barrie, Ontario L4M 7G1, Canada
  • Dermatrials Research Inc.
    Hamilton, Ontario L8N 1Y2, Canada
  • Lovegrove Dermatology - Probity - PPDS
    London, Ontario N6A 5R9, Canada
  • DermEffects - Probity - PPDS
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • DermEdge Research
    Mississauga, Ontario L4Y 4C5, Canada
  • Clintrial s.r.o.
    Prague, Praha 10 10100, Czechia
  • Pratia Pardubice a.s. - PRATIA - PPDS
    Pardubice, 530 02, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
  • Pratia Prague s.r.o. - PRATIA - PPDS
    Prague, 13000, Czechia
  • Kozni ambulance Fialova, s.r.o. - CRC - PPDS
    Prague, 160 00, Czechia
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Praxis Dr. med. Virgil-Oreste Mihaescu Facharzt fr Dermatologie und STD
    Augsburg, Bavaria 86150, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt am Main, Hesse 60590, Germany
  • Universitätsklinikum Münster
    Münster, North Rhine-Westphalia 48149, Germany
  • Universitätsklinikum Carl Gustav Carus an der TU
    Dresden, 1307, Germany
  • MensingDerma Research GmbH
    Hamburg, 22391, Germany
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Allergo-Derm Bakos Kft
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Gyongyosi Bugat Pal Korhaz
    Gyöngyös, 3200, Hungary
  • MedMare Bt
    Veszprém, 8200, Hungary
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 450-0003, Japan
  • Medical Corporation Kojinkai Sapporo Skin Clinic
    Sapporo, Hakkaido 060-0063, Japan
  • Katahira Dermatology Urology Clinic
    Kagoshima, Kagoshima-ken 890-0063, Japan
  • Ohyama Dermatology Clinic
    Kumamoto, Kumamoto 861-4101, Japan
  • Kume Clinic
    Sakai-shi, Osaka 593-8324, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Tachikawa Dermatology Clinic
    Tachikawa, Tokyo 190-0023, Japan
  • Shirasaki dermatology clinic
    Takaoka, Toyama 933-0871, Japan
  • Igarashi Dermatological Clinic
    Tokyo, Japan
  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu
    Wroclaw, Lower Silesian Voivodeship 50-381, Poland
  • Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
  • Clinical Best Solutions
    Warsaw, Masovian Voivodeship 00-710, Poland
  • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
    Rzeszów, Podkarpackie Voivodeship 35-055, Poland
  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku
    Gdansk, Pomeranian Voivodeship 80-382, Poland
  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdyni
    Gdynia, Pomeranian Voivodeship 81-537, Poland
  • Synexus Polska Sp. z o.o. Oddzial w Czestochowie
    Częstochowa, Silesian Voivodeship 42-202, Poland
  • Laser Clinic Dermatologia Laserowa Medycyna Estetyczna
    Szczecin, West Pomeranian Voivodeship 70-332, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Centrum Medyczne Reuma Park NZOZ
    Warsaw, 02-665, Poland
  • Dermoklinika Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak
    Lodz, Łódź Voivodeship 90-436, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jul 2025, 8 months.

Results were first posted in Aug 2026, 1 year after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Sep 19, 2024
StartActual
Oct 25, 2024
Primary completionActual
Jul 24, 2025
CompletionActual
Sep 4, 2025
Results first posted
Aug 18, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06602219
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 25, 2024
Primary completion
Jul 24, 2025
Completion
Sep 4, 2025
Results posted
Aug 18, 2026
Last update
Aug 18, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simepdekinra

Start the discussion